HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Provided By Globe Newswire
Last update: Sep 13, 2022
Nearing Completion of Patient Recruitment in
FDA Pivotal Clinical Validation Study of MyoVista®
Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year
Read more at globenewswire.com3.78
-0.12 (-3.08%)
NASDAQ:HSCSW (7/1/2025, 8:32:29 PM)
0.0914
+0.02 (+29.83%)
Find more stocks in the Stock Screener
